Clovis Oncology Inc (CLVS.xnas) is a commercial-stage biotechnology company headquartered in Colorado, America. Clovis is focusing on acquiring, developing and commercialising innovative anti-cancer treatments across the United States but also in Europe and other international markets and employs 429 people. Clovis’ product development programs target specific subsets of cancer and seek to develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. The company’s appropriate technology for each program, and expertise gained regulatory approvals and support internationally commercialisation that parallels Clovis’ regulatory and commercialisation paths. Clovis Oncology Inc stock (CLVS.xnas) is listed on NASDAQ, had a market capitalisation of $350.94M (USD) as of December 2021 and $165M (USD) in 2020 yearly revenues. Clovis Oncology’s only approved product Rubraca reported sales of $74.9M (USD) and holds bright prospects for the ovarian cancer market. Clovis is also evaluating Rubraca in several label expansion studies across ovarian cancer is being evaluated in a phase III ATHENA study, both as a monotherapy and in combination with Bristol Myers’ BMY Opdivo in advanced ovarian cancer as a first-line maintenance treatment and data from this study is expected in 2022.
Clovis Oncology Inc (CLVS)
Explore Clovis Oncology Inc (CLVS) share price insights and trends for informed trading decisions. Stay informed with FP Markets Bahrain.